4.7 Review

Targeting WEE1 Kinase in Cancer

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 37, Issue 10, Pages 872-881

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2016.06.006

Keywords

-

Funding

  1. National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) [R21NS084084]
  2. University of Colorado Computational Chemistry and Biology Core Facility
  3. University of Colorado Medicinal Chemistry Core Facility
  4. NIH/National Center for Advancing Translational Sciences (NCATS) Colorado Clinical and Translational Science Award (CTSA) grant [UL1 TR001082]

Ask authors/readers for more resources

WEE1 kinase plays a crucial role in the G2-M cell-cycle checkpoint arrest for DNA repair before mitotic entry. Normal cells repair damaged DNA during G1 arrest; however, cancer cells often have a deficient G1-S checkpoint and depend on a functional G2-M checkpoint for DNA repair. WEE1 is expressed at high levels in various cancer types including breast cancers, leukemia, melanoma, and adult and pediatric brain tumors. Many of these cancers are treated with DNA-damaging agents; therefore, targeting WEE1 for inhibition and compromising the G2-M checkpoint presents an opportunity to potentiate therapy. In this review we summarize the current WEE1 inhibitors, the potential for further inhibitor development, and the challenges in the clinic for the WEE1 inhibitor strategy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available